DXS INTERNATIONAL PLC
The Board of DXS International plc (the “Company”), the NEX quoted clinical decision support developer and supplier of clinical decision support systems is pleased to confirm that at the AGM today, the CEO, David Immelman, will introduce the new product suite recently launched by the Company and set out the aspirations and targets for the Company over the next five years.
DXS has recently launched the MyVytalCare and DXS ExpertCare products aimed at treating Long Term Conditions both from the patient and the GP’s point of view.
The new products include an App which is interactive with the patient while providing the clinician with expert NICE compliant diagnostic and prescribing advice.
Financial targets include achieving a six-fold increase in turnover over the next five years and post-tax profits in excess on £7m p.a.
David Immelman, the CEO, will say “We are pleased to confirm that after a period of consolidation and major investment in our Research and Development of £1m p.a. over several years, we continue to ignore the tech hype of other internet-based offerings and remain focused on long-term systemic transformation.
To succeed in healthcare requires companies that understand the complexity of healthcare markets, the 18-month long sales cycles, the importance of combining new tech with legacy systems and the resistance to change. We believe that we have the skills, knowledge and experience earned over many years which will allow us to confront the issues facing the NHS and abroad”.
The Presentation will be made available on the Company’s website following the AGM.
The Directors of DXS International plc accept responsibility for this announcement
City & Merchant
|0207 101 7676|
|Level 17, Dashwood House|
69 Old Broad Street,
Note to Editors:
DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.